# EDGAR Filing Document

**Accession Number:** 0001827401
**File Stem:** 0002060755-26-000031
**Filing Date:** 2026-5
**Character Count:** 4704
**Document Hash:** 3e287200b09108212e1503175794a337
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002060755-26-000031.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0002060755-26-000031

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260526

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40997
- **FILM NUMBER:** 261028156

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2026**

Commission File No. **001-40997**

**BRIGHT MINDS BIOSCIENCES INC.**<br>(Translation of registrant's name into English)

---

| | |
|:---|:---|
| **400 N Aberdeen St Suite 900**<br>**Chicago, IL 60642**<br>(U.S. Corporate headquarters) | **1122 Mainland St #228**<br>**Vancouver, BC V6B 5L1**<br>(Canadian Corporate headquarters) |

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [ ] **Form 40-F [ X ]**

------

**SUBMITTED HEREWITH**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibits** |  |
| 99.1 | [News Release dated](ex991-20260526.htm)[May 2](ex991-20260526.htm)[6](ex991-20260526.htm)[, 202](ex991-20260526.htm)[6](ex991-20260526.htm) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BRIGHT MINDS BIOSCIENCES INC.**

*/s/ Ryan Cheung*

Ryan Cheung<br>Chief Financial Officer

Date: May 27, 2026

------

## Exhibit 99.1

**FOR IMMEDIATE RELEASE**

**Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference**

New York City – May 26, 2026 – Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

**DATE:** Wednesday, June 3, 2026

**TIME:** 4:20PM EDT

**WEBCAST:**https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/bvVWVgeHmHjUbuFuDEjCS8

The live and archived webcast will be accessible from the Company's website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 30 days.

Bright Minds further releases that the Company has granted stock options (the "**Options**") to certain directors, officers and consultants of the Company to purchase an aggregate of 109,000 common shares in the capital of the Company (the "**Shares**") pursuant to the Company's share option plan. The Options are exercisable at a price of US$83.40 per Share for a period of five (5) years from the date of grant. The Options vest in four (4) equal annual instalments of 25% each, commencing on the first anniversary of the date of grant.

**About Bright Minds Biosciences**

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

**Contact Information**

Investor Relations

Lisa M. Wilson

T: 212-452-2793

E: lwilson@insitecony.com

------

Alex Vasilkevich

Chief Operating Officer

Bright Minds Biosciences Inc.

T: 414-731-6422

E: alex@brightmindsbio.com